Molecular Basis for Immunoglobulin M Specificity to Epitopes inCryptococcus neoformansPolysaccharide That Elicit Protective and Nonprotective Antibodies
Open Access
- 1 May 2001
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (5) , 3398-3409
- https://doi.org/10.1128/iai.69.5.3398-3409.2001
Abstract
The protective efficacy of antibodies (Abs) toCryptococcus neoformansglucuronoxylomannan (GXM) is dependent on Ab fine specificity. Two clonally related immunoglobulin M monoclonal Abs (MAbs) (12A1 and 13F1) differ in fine specificity and protective efficacy, presumably due to variable (V)-region sequence differences resulting from somatic mutations. MAb 12A1 is protective and produces annular immunofluorescence (IF) on serotype DC. neoformans,while MAb 13F1 is not protective and produces punctate IF. To determine the Ab molecular determinants responsible for the IF pattern, site-directed mutagenesis of the MAb 12A1 heavy-chain V region (VH) was followed by serological and functional studies of the various mutants. Changing two selected amino acids in the 12A1 VHbinding cavity to the corresponding residues in the 13F1 VHaltered the IF pattern from annular to punctate, reduced opsonic efficacy, and abolished recognition by an anti-idiotypic Ab. Analysis of the binding of the various mutants to peptide mimetics revealed that different amino acids were responsible for GXM binding and peptide specificity. The results suggest that V-region motifs associated with annular binding and opsonic activity may be predictive of Ab efficacy againstC. neoformans. This has important implications for immunotherapy and vaccine design that are reinforced by the finding that GXM and peptide reactivities are determined by different amino acid residues.Keywords
This publication has 70 references indexed in Scilit:
- Quantitative and Qualitative Differences in the Serum Antibody Profiles of Human Immunodeficiency Virus–Infected Persons with and withoutCryptococcus neoformansMeningitisThe Journal of Infectious Diseases, 1999
- Monoclonal Antibody–Mediated Toxicity inCryptococcus neoformansInfection: Mechanism and Relationship to Antibody IsotypeThe Journal of Infectious Diseases, 1999
- The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopesJournal of Molecular Biology, 1997
- Epitope Location in the Cryptococcus neoformans Capsule Is a Determinant of Antibody EfficacyThe Journal of Experimental Medicine, 1997
- Peptide Libraries Define the Fine Specificity of Anti-polysaccharide Antibodies toCryptococcus neoformansJournal of Molecular Biology, 1996
- J774 Murine Macrophage-like Cell Interactions with Cryptococcus neoformans in the Presence and Absence of OpsoninsThe Journal of Infectious Diseases, 1996
- Canonical Structure Repertoire of the Antigen-binding Site of Immunoglobulins Suggests Strong Geometrical Restrictions Associated to the Mechanism of Immune RecognitionJournal of Molecular Biology, 1995
- Cryptococcus neoformans infection can elicit protective antibodies in miceCanadian Journal of Microbiology, 1994
- Antibodies Elicited by a Cryptococcus neoformans-Tetanus Toxoid Conjugate Vaccine Have the Same Specificity as Those Elicited in InfectionThe Journal of Infectious Diseases, 1992
- The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.The Journal of Experimental Medicine, 1991